Ozgur Sahin

Loxigen, Inc.

NIH Rank #7359
  • R01 Holder
  • Early Career

NIH Funding · FY2024

Total Funding
$1.7M
Fiscal year 2024
Grants Awarded
3
Active NIH grants
National Rank
#7,359
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $1.7M across 3 grants · National rank #7359.

Top grants by award amount

Ozgur Sahin's NIH grant portfolio, ranked by award amount.

  • 4R42CA275622-02R42
    Developing novel LOX inhibitors to target chemotherapy resistant TNBC
    $992.9K
    award amount
  • 5R01CA267101-04R01
    Overcoming chemoresistance in triple negative breast cancer
    $352.3K
    award amount
  • 5R01CA251374-04R01
    Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
    $321.8K
    award amount

Affiliations

Institutions that have administered grants for Ozgur Sahin.

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    Loxigen, Inc.
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #7359
  5. 2024
    Multi-Institutional Research
    Awards at 2 institutions